XML 48 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 08, 2017
Jul. 06, 2017
Sep. 01, 2014
Jun. 23, 2018
Apr. 18, 2018
May 31, 2017
Oct. 25, 2016
Jun. 30, 2016
May 31, 2016
Dec. 31, 2015
Jan. 31, 2015
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Jun. 21, 2016
Operating lease periodic payment                     $ 709              
Frequency of periodic payment                     Monthly              
Operating lease rental expense                       $ 2,147   $ 2,126 $ 4,272 $ 4,251    
Operating lease expiration date                     May 31, 2017              
Lease agreement description                    

The Company has negotiated and entered into a two-year amendment to that lease that commenced as of June 1, 2017 through May 31, 2019. The monthly rate from June 1, 2017 through May 31, 2018 is $709 per month and increases to $730 per month from June 1, 2018 through May 31, 2019.

              
Decahedron [Member]                                    
Operating lease periodic payment             $ 2,470                      
Operating lease rental expense                             15,753 12,076    
Operating lease expiration date             Oct. 24, 2021                      
Private Placement [Member]                                    
Commitments and contingencies description

On August 8, 2017, the Company entered into an agreement with a third-party placement agent (the “Agent”) who will serve as the Company’s exclusive placement agent or sole book running manager with respect to any offerings of equity or equity-linked securities as well as any debt offering with the two organizations named in the agreement (the “Offering”) for a period of 120 days. In the event that an Offering is agreed upon by the Agent and the Company, the Company shall provide payment as follows: (1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering.

                                  
Lease agreement description

In connection with the Company’s November 16, 2017 Note offering, the Agent received a cash commission of $240,000, equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of Common Stock issued or issuable in the offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 53,600 shares); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or May 16, 2018.

                                  
Agent commission recevied $ 240,000                                  
SkyPharm [Member]                                    
Operating lease periodic payment     $ 4,802     $ 1,250                        
Frequency of periodic payment     Monthly     Monthly                        
Operating lease rental expense                       $ 32,684   25,198 65,367 50,397    
Term of operating lease     6 years                              
Advisory agreement, description        

SkyPharm S.A. entered into a ten-year Advisory Agreement with Synthesis Management Limited (the “Advisor”). The Advisor was retained to assist SkyPharm to secure corporate finance capital. The Advisor shall be paid €104,000 per year during the ten-year term.

                          
SkyPharm [Member] | Additional space [Member]                                    
Operating lease periodic payment               $ 2,021 $ 886                  
Frequency of periodic payment               Monthly Monthly                  
SkyPharm [Member] | First Floor [Member]                                    
Operating lease periodic payment                   $ 886                
Frequency of periodic payment                   Monthly                
SkyPharm [Member] | MediHelm S.A. [Member]                                    
Operating lease periodic payment                             $ 8,758      
Frequency of periodic payment                             Monthly      
Operating lease rental expense                         $ 33,180   $ 24,891      
CC Pharma GmbH [Member]                                    
Non-refundable fee                                   $ 454,800
Expense paid   $ 454,800                             $ 454,800  
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]                                    
Operating lease periodic payment                             $ 1,500      
Common stock shares reserved                       200,000     200,000      
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Preclinical Trials [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]                                    
Common stock shares reserved                       50,000     50,000      
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | conclusion of Phase I testing [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]                                    
Common stock shares reserved                       50,000     50,000      
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Phase II testing [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]                                    
Common stock shares reserved                       50,000     50,000      
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Phase III testing [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]                                    
Common stock shares reserved                       50,000     50,000      
Amplerissimo [Member]                                    
Operating lease periodic payment                             $ 122      
Frequency of periodic payment                             Monthly      
Operating lease rental expense                       $ 399   $ 358 $ 799 $ 715    
Operating lease renewal date                             Jul. 31, 2018      
Stock Purchase Agreement [Member]                                    
Business acquisition, description      

The purchase price payable in cash is €700,000. Closing of the acquisition is subject to satisfactory completion of due diligence, delivery of audited and interim financial statements of Cosmofarm subject to being audited by PCAOB auditors, no material adverse change in the business or financial condition of Cosmofarm, all necessary consents and approvals to complete the acquisition have been obtained and other customary closing conditions. As of June 30 2017, Cosmofarm is undergoing an audit of the company’s financial statements for the last two years by a PCAOB audit firm, the SPA has not closed and Cosmos has not paid the €700,000.